Description: Imunon is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting preclinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate its PLACCINE platform. Imunon’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Home Page: www.imunon.com
IMNN Technical Analysis
997 Lenox Drive
Lawrenceville,
NJ
08648
United States
Phone:
609 896 9100
Officers
| Name | Title |
|---|---|
| Mr. Michael H. Tardugno | Exec. Chairman |
| Mr. Jeffrey W. Church CPA, CPA | CFO, Exec. VP & Corp. Sec. |
| Dr. Khursheed Anwer M.B.A., Ph.D. | Exec. VP & Chief Scientific Officer |
| Dr. Nicholas Borys M.D. | Exec. VP & Chief Medical Officer |
| Dr. Corinne Le Goff M.B.A., Pharm.D. | CEO, Pres & Director |
| Mr. Timothy J. Tumminello CPA | Chief Accounting Officer & Controller |
| Ms. Marianne M. Lambertson | VP of Communications & Investor Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2445 |
| Price-to-Sales TTM: | 20.5187 |
| IPO Date: | 1999-03-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |